Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Swoboda

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Leukemia Research|June 18, 2021
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapyAnthony M Hunter, Najla Al Ali, Anne Mai, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2021
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid MalignanciesQuinto J Gesiotto, David M Swoboda, Rory M Shallis, et al.
American Journal of Hematology|February 18, 2022
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?Somedeb Ball, Akriti G Jain, Luis E Aguirre, et al.
Hematological Oncology|May 16, 2026
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid LeukemiaGeorgio Medawar, Jean-Sebastien Anoma, Elizabeth Hill, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2021
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid MalignanciesRory M Shallis, Jan Philipp Bewersdorf, David M Swoboda, et al.
Molecular Cell|April 3, 2026
U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAsGloria R Garcia, Murali Palangat, Josquin Moraly, et al.
American Journal of Hematology|January 27, 2021
Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemiaDaniel R Richardson, David M Swoboda, Dominic T Moore, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 25, 2022
Corrigendum to 'BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression' European Neuropsychopharmacology Volume 58, May 2022, Pages 103-108Alexandra Schosser, Daniela Fischer-Hansal, Marleen M Swoboda, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 22, 2022
BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression: to be submitted to: European NeuropsychopharmacologyAlexandra Schosser, Daniela Fischer-Hansal, Marleen M Swoboda, et al.
Translational Behavioral Medicine|April 13, 2012
Integrating eHealth With Human Services for Breast Cancer PatientsRobert P Hawkins, Suzanne Pingree, Timothy Baker, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Leukemia Research|June 18, 2021
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapyAnthony M Hunter, Najla Al Ali, Anne Mai, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2021
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid MalignanciesQuinto J Gesiotto, David M Swoboda, Rory M Shallis, et al.
American Journal of Hematology|February 18, 2022
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?Somedeb Ball, Akriti G Jain, Luis E Aguirre, et al.
Hematological Oncology|May 16, 2026
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid LeukemiaGeorgio Medawar, Jean-Sebastien Anoma, Elizabeth Hill, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2021
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid MalignanciesRory M Shallis, Jan Philipp Bewersdorf, David M Swoboda, et al.
Molecular Cell|April 3, 2026
U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAsGloria R Garcia, Murali Palangat, Josquin Moraly, et al.
American Journal of Hematology|January 27, 2021
Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemiaDaniel R Richardson, David M Swoboda, Dominic T Moore, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 25, 2022
Corrigendum to 'BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression' European Neuropsychopharmacology Volume 58, May 2022, Pages 103-108Alexandra Schosser, Daniela Fischer-Hansal, Marleen M Swoboda, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 22, 2022
BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression: to be submitted to: European NeuropsychopharmacologyAlexandra Schosser, Daniela Fischer-Hansal, Marleen M Swoboda, et al.
Translational Behavioral Medicine|April 13, 2012
Integrating eHealth With Human Services for Breast Cancer PatientsRobert P Hawkins, Suzanne Pingree, Timothy Baker, et al.
Pageof 14